To the editor:

Severe congenital neutropenia (CN), a congenital disorder of hematopoiesis and a preleukemic predisposition, has been used as a model for multistep pathogenesis of leukemia. CSF3R gene mutations are regarded as an early marker of malignant transformation in CN.1,2  A commonly accepted model is that the acquisition of CSF3R mutations, which confer a growth advantage to myeloid progenitors,3  is an early and specific event, typically followed by other nonspecific genetic changes necessary for complete transformation. Common genetic abnormalities like acquired clonal cytogenetic alterations4,5  or activating RAS mutations5  have also been observed to be associated with CN-related myelodysplastic syndrome (MDS)/leukemia. The assumption of RAS mutations as frequent genetic aberrations in the malignant transformation of CN6,7  is mainly based on the original study on RAS mutations in CN by Kalra et al5  (5/11 patients with CN and MDS/leukemia).

To further investigate the role of RAS mutations in CN, we screened for mutations of KRAS and NRAS in 45 CN patients. The patients were selected for secondary malignancies (n = 15) or for detection of a CSF3R mutation (n = 30). Surprisingly, we detected RAS mutations in only 2 CN patients with malignant transformation (Table 1 no. 9, NRAS c.37G > C, p.G13R; no. 10, KRAS c.182A > C, p.Q61P). Chromosomal abnormalities were present in all 12 patients with secondary malignancies for whom data were available and included monosomy 7 (n = 4), trisomies (n = 3), deletions (n = 2), and translocations (n = 5). Truncating CSF3R mutations2  were detected in 9 of 15 patients with secondary malignancies (Table 1). The group of CN patients with secondary malignancies with CSF3R mutations did not obviously differ from that without CSF3R mutations with regard to the genetic background of CN or to specific chromosomal anomalies.

Table 1

CSF3R and RAS mutations and cytogenetic aberrations in patients with CN and secondary malignancies

Patient IDCN mutations*MalignancyChromosomal aberrationsCSF3R mutationsRAS mutations
This study      
    1 ELANE AML 46,XX,t(p1;q3); elongation of 5q p.Q731X — 
    2 No AML 46,XY,t(6;19),(q112,q13) p.Q731X — 
    3 ELANE AML 46,XY,−7,+21 P.Q731X — 
    4 ELANE AML 46,XX / 45XX,−7 in 1 clone / 92,XXXX in 1 clone p.Q707X, p.Q718X, p.Q726X, p.Q729X — 
    5 ELANE AML 47,XX,+8 p.Q716X, p.Q718X, p.Q726X, p.Q729X — 
    6 ELANE MDS (AML) 47,XX,5q−,+21 p.Q726X, p.Q731X — 
    7 ELANE ALL 46,XX,der(2)t(2;3)(q37;q21, del(5)(q13q33)[8]/46,XX[7] p.Q718X, p.Q726X — 
    8 HAX1 ALL ND p.K762X — 
    9 No CMML 45,XY,−7 p.Q718X, p.Q762X NRAS, p.G13R 
    10 ELANE AML 45,XX,−7 — KRAS, p.Q61P 
    11 ELANE AML 46,XX, der(7)t(3;7)(?;p22) — — 
    12 ELANE AML 46,XY,t(9;11) — — 
    13 No AML 45,XX,−7 — — 
    14 ELANE AML ND — — 
    15 ELANE MDS (RAEB) ND — — 
Patients from Kalra et al5       
    6/F ND AML 46,XX / 45,XX, −7 — NRAS, p.G12D 
    7/F ND AML 46,XX, −7,+(del)(20q) — NRAS, p.G12D 
    8/F ND AML 46,XX / 47,XX,+mar — NRAS, p.G12D 
Patient IDCN mutations*MalignancyChromosomal aberrationsCSF3R mutationsRAS mutations
This study      
    1 ELANE AML 46,XX,t(p1;q3); elongation of 5q p.Q731X — 
    2 No AML 46,XY,t(6;19),(q112,q13) p.Q731X — 
    3 ELANE AML 46,XY,−7,+21 P.Q731X — 
    4 ELANE AML 46,XX / 45XX,−7 in 1 clone / 92,XXXX in 1 clone p.Q707X, p.Q718X, p.Q726X, p.Q729X — 
    5 ELANE AML 47,XX,+8 p.Q716X, p.Q718X, p.Q726X, p.Q729X — 
    6 ELANE MDS (AML) 47,XX,5q−,+21 p.Q726X, p.Q731X — 
    7 ELANE ALL 46,XX,der(2)t(2;3)(q37;q21, del(5)(q13q33)[8]/46,XX[7] p.Q718X, p.Q726X — 
    8 HAX1 ALL ND p.K762X — 
    9 No CMML 45,XY,−7 p.Q718X, p.Q762X NRAS, p.G13R 
    10 ELANE AML 45,XX,−7 — KRAS, p.Q61P 
    11 ELANE AML 46,XX, der(7)t(3;7)(?;p22) — — 
    12 ELANE AML 46,XY,t(9;11) — — 
    13 No AML 45,XX,−7 — — 
    14 ELANE AML ND — — 
    15 ELANE MDS (RAEB) ND — — 
Patients from Kalra et al5       
    6/F ND AML 46,XX / 45,XX, −7 — NRAS, p.G12D 
    7/F ND AML 46,XX, −7,+(del)(20q) — NRAS, p.G12D 
    8/F ND AML 46,XX / 47,XX,+mar — NRAS, p.G12D 

Shown are results of the present study and results of CSF3R mutation analysis in CN patients with MDS/leukemia and RAS mutations described by Kalra et al.5  Material from 3 of 5 patients originally described by Kalra et al was made available for retrospective analysis of CSF3R mutations.

ALL indicates acute lymphocytic leukemia; AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia ; CN, severe congenital neutropenia; —, no mutation; and ND, not determined.

*

CN candidate genes in which mutations have been detected are listed in this column. No indicates no mutation in ELANE or HAX1 genes.

This patient has been described in detail in an earlier publication.8 

Because there was an obvious discrepancy between the data of the original study of Kalra et al and the results of our present study (P < .05 using Fisher exact probability test), we asked the authors to send us DNA from their RAS mutation–positive CN patients to screen these specimens for CSF3R mutations. DNA was available for 3 of the 5 patients with RAS mutations described there. Although we could demonstrate that the majority of patients with CN and MDS/leukemia harbor acquired CSF3R mutations (18/23, 78%),2  none of these CN patients with secondary MDS/leukemia and RAS mutation had a CSF3R mutation (Table 1). Interestingly, in a recent study investigating patterns of mutations in de novo acute myeloid leukemia (AML) and AML secondary to CN, the authors also detected a very low percentage of RAS mutations in the group of CN AML/MDS patients (1/14, 7%).9  With the exception of one patient with CN and secondary chronic myelomonocytic leukemia the occurrence of CSF3R and RAS mutations was mutually exclusive.

A model of cooperativity of genetic aberrations in leukemogenesis has been proposed postulating at least 2 broad complementation groups of mutations: one class of mutations that confers a proliferative and/or survival advantage to hematopoietic progenitors, and another group of mutations resulting in a differentiation block in hematopoiesis.10  The results of our study demonstrate that CSF3R and RAS mutations most likely do not act cooperatively in leukemogenesis, as generally agreed so far, but might have overlapping functions and may replace each other in the deregulation of common signaling pathways.

Approval for this study was obtained from the institutional review board of the Hannover Medical School. Informed consent was provided according to the Declaration of Helsinki.

Acknowledgments: The authors thank the Severe Chronic Neutropenia European Registry (SCNER) and all physicians who referred the patients to our study. A special thanks to Kevin M. Shannon for providing materials for retrospective analyses and for critical discussions on the manuscript.

This work was supported by grants from the Federal Ministry of Education and Research (German Network on Congenital Bone Marrow Failure Syndromes) and from the Deutsche Krebshilfe (grant no. 10-1105).

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Manuela Germeshausen, Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg-Str 1, D-30625 Hannover, Germany; e-mail: [email protected].

1
Dong
 
F
Brynes
 
RK
Tidow
 
N
Welte
 
K
Lowenberg
 
B
Touw
 
IP
Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia.
N Engl J Med
1995
, vol. 
333
 (pg. 
487
-
493
)
2
Germeshausen
 
M
Ballmaier
 
M
Welte
 
K
Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey.
Blood
2007
, vol. 
109
 (pg. 
93
-
99
)
3
Germeshausen
 
M
Welte
 
K
Ballmaier
 
M
In vivo expansion of cells expressing acquired CSF3R mutations in patients with severe congenital neutropenia.
Blood
2009
, vol. 
113
 (pg. 
668
-
670
)
4
Freedman
 
M
Bonilla
 
MA
Fier
 
C
et al. 
Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy.
Blood
2000
, vol. 
96
 (pg. 
429
-
436
)
5
Kalra
 
R
Dale
 
D
Freedman
 
M
et al. 
Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia.
Blood
1995
, vol. 
86
 (pg. 
4579
-
4586
)
6
Freedman
 
MH
Alter
 
BP
Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias.
Semin Hematol
2002
, vol. 
39
 (pg. 
128
-
133
)
7
Zeidler
 
C
Schwinzer
 
B
Welte
 
K
Congenital neutropenias.
Rev Clin Exp Hematol
2003
, vol. 
7
 (pg. 
72
-
83
)
8
Germeshausen
 
M
Schulze
 
H
Kratz
 
C
et al. 
An acquired G-CSF receptor mutation results in increased proliferation of CMML cells from a patient with severe congenital neutropenia.
Leukemia
2005
, vol. 
19
 (pg. 
611
-
617
)
9
Link
 
DC
Kunter
 
G
Kasai
 
Y
et al. 
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
Blood
2007
, vol. 
110
 (pg. 
1648
-
1655
)
10
Gilliland
 
DG
Tallman
 
MS
Focus on acute leukemias.
Cancer Cell
2002
, vol. 
1
 (pg. 
417
-
420
)
Sign in via your Institution